Altered neuroendocrine regulation of luteinizing hormone secretion in postmenopausal women with Parkinson's disease.
The secretion of gonadotropins and the role exerted by the endogenous opioid system on luteinizing hormone (LH) secretion were investigated in 6 postmenopausal women affected by idiopathic Parkinson's disease (PD) as well as in 6 age- and weight-matched normal postmenopausal women as controls. The mean plasma follicle-stimulating hormone (FSH) and LH levels were evaluated both under basal conditions and after 20 days of conjugated estrogen administration (1.25 mg/day). At the same time, the activity of the endogenous opioid system was evaluated, as well as the LH response to the 4-hour infusion of the opioid antagonist naloxone (1.6 mg i.v. bolus followed by 1.6 mg/h). Both before and during estrogen administration, plasma FSH levels were similar in the two groups of subjects, whereas plasma LH levels were significantly lower (p less than 0.01) in parkinsonian than in control women. In each subject estrogen administration significantly blunted (p less than 0.01) plasma FSH levels. Plasma LH levels were reduced only in controls (p less than 0.05), but not in women with PD. In each subject, before estrogen administration, the plasma LH levels did not vary during naloxone infusion. In control women after 20 days of estrogen administration, the plasma LH levels significantly increased during naloxone infusion (p less than 0.01). By contrast, in women with PD, conjugated estrogens failed to restore the LH response to naloxone. The present results suggest that the neurotransmitter mechanisms, which regulate LH secretion, are altered, and, in particular, the activity of the endogenous opioid system is deficient in women with PD.
Department of Obstetrics and Gynecology, University of Pisa, Italy.
A
A
Cagnacci
G B
GB
Melis
R
R
Soldani
U
U
Bonuccelli
P
P
Piccini
A
A
Napolitano
A
A
Muratorio
P
P
Fioretti
D000368:Aged; D004723:Endorphins / Q000172:deficiency / Q000502:physiology; D004967:Estrogens / Q000494:pharmacology / Q000627:therapeutic use; D005260:Female; D005640:Follicle Stimulating Hormone / Q000097:blood; D006801:Humans; D007700:Kinetics; D007986:Luteinizing Hormone / Q000097:blood / Q000378:metabolism*; D008593:Menopause; D008875:Middle Aged; D009270:Naloxone; D018377:Neurotransmitter Agents / Q000502:physiology*; D010300:Parkinson Disease / Q000503:physiopathology*
D004723:Endorphins; D004967:Estrogens; D018377:Neurotransmitter Agents; D009270:Naloxone; D007986:Luteinizing Hormone; D005640:Follicle Stimulating Hormone